Invest in intelligence that delivers

EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy

Data from Spherix Global Insights’ second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan), opportunities for pipeline agents to make an impact remain. EXTON, PA., April 30, 2024 – Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by […]

Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market

Takeda’s line extension has outpaced other concurrent launches in adoption and familiarity three months post launch, according to Spherix Global Insights. Exton, PA., March 22, 2024 – The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh (mirikizumab), the first FDA approved IL-23 […]

Stakes Are High for Regeneron’s Eylea HD as Genentech’s Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights

Navigating the landscape of Wet AMD Therapies During AMD Awareness Month EXTON, PA., February 8, 2024 — As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD, the need for optimal treatment solutions becomes increasingly evident. Wet AMD poses a particularly severe threat to vision, necessitating […]

Market Study Reports Secukinumab Emerged as a Leading Treatment for HS

To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists. In a significant development for patients with hidradenitis suppurativa (HS), the FDA granted approval to secukinumab (Cosentyx, Novartis) last fall. This marked a milestone as secukinumab became the second biologic, alongside adalimumab […]

Chart review shows nephrologists prescribing more SGLT2 inhibitors

A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with chronic kidney disease, according to a press release. “Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for [mineralocorticoid receptor agonists] MRAs and [glucagon-like peptide-1] […]

Novartis’ Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie’s Humira

Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix Global Insights. [Exton, PA., January 10, 2024] — In late October 2023, the FDA granted approval to Novartis’ Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the second biologic approved alongside AbbVie’s Humira […]

US biosimilar market in 2023: Sea change or slow drip?

News pertaining to biosimilars came at a fast and furious pace in 2023. This was the year of the big “deluge” in biosimilars, including those designated as interchangeable, hitting the rheumatology market in the United States. As many as nine biosimilars for adalimumab (Humira, AbbVie) alone became available for the first time for U.S. patients, […]

Survey: Halting neurodegeneration chief concern in Huntington’s disease

According to results of a recent survey, more than 80% of U.S.-based neurologists agreed that a major unmet need in confronting Huntington’s disease is halting neurodegeneration prior to the onset of symptoms. Furthermore, an equal number of professionals in the specialty expressed frustration with the absence of meaningful treatments to slow cognitive decline. Spherix Global […]

Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion

Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for MRAs and GLP-1s, according to Spherix Global Insights.   EXTON, Pa., Jan 03, 2024 – Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion […]

US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority

According to Spherix Global Insights’ first market landscape study on Huntington’s disease, neurologists are staking their hopes on gene therapy. EXTON, Pa., January 3, 2024 – Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not only motor function – causing symptoms […]

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:

HEMATOLOGY

Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.